Am­gen posts up­beat as­sess­ment of PhII KRAS da­ta on AMG510 — but there's no clear pic­ture of what re­searchers saw

It’s not un­usu­al to be left want­i­ng af­ter read­ing a top-line press re­lease on close­ly-watched tri­al da­ta. But Am­gen is tak­ing it to a whole …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.